Yibei Dai
Overview
Explore the profile of Yibei Dai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Chen T, Ping Y, Dai Y, Yu P, Xie Y, et al.
Small
. 2023 Dec;
20(20):e2307985.
PMID: 38084466
Genetic variations are always related to human diseases or susceptibility to therapies. Nucleic acid probes that precisely distinguish closely related sequences become an indispensable requisite both in research and clinical...
2.
Sun T, Cao Y, Huang T, Sang Y, Dai Y, Tao Z
J Clin Lab Anal
. 2022 Sep;
36(11):e24709.
PMID: 36125921
Background: Acute kidney injury is a common clinical problem with no sensitive and specific diagnostic biomarkers and definitive treatments. The underlying molecular mechanisms of acute kidney injury are unclear. Therefore,...
3.
Yu P, Dai Y, Zhuang T, Yue X, Chen Y, Wang X, et al.
Oxid Med Cell Longev
. 2022 Aug;
2022:8761112.
PMID: 36035209
Background: The acquisition of castration resistance is lethal and inevitable in most prostate cancer patients under hormone therapy. However, effective biomarkers and therapeutic targets for castration-resistant prostate cancer remain to...
4.
Zhang L, Wang D, Dai Y, Wang X, Cao Y, Liu W, et al.
Front Aging Neurosci
. 2022 Jun;
14:863673.
PMID: 35645782
Background: Predicting amnestic mild cognitive impairment (aMCI) in conversion and Alzheimer's disease (AD) remains a daunting task. Standard diagnostic procedures for AD population are reliant on neuroimaging features (positron emission...
5.
Dai Y, Wang Y, Cao Y, Yu P, Zhang L, Liu Z, et al.
Front Oncol
. 2021 Dec;
11:777684.
PMID: 34900726
Introduction: Prostate cancer (PCa) is one of the most frequently diagnosed cancers and the leading cause of cancer death in males worldwide. Although prostate-specific antigen (PSA) screening has considerably improved...
6.
Cao Y, Dai Y, Zhang L, Wang D, Hu W, Yu Q, et al.
J Inflamm Res
. 2021 Dec;
14:6409-6419.
PMID: 34880643
Background: Fecal biomarkers have emerged as one of the most useful tools for clinical management of inflammatory bowel disease (IBD). Oncostatin M (OSM), like fecal calprotectin (FC), is highly expressed...
7.
Cao Y, Dai Y, Zhang L, Wang D, Yu Q, Hu W, et al.
Clin Biochem
. 2021 Nov;
100:35-41.
PMID: 34843732
Background: Although endoscopy is the gold standard to assess disease activity and infliximab efficacy in inflammatory bowel disease (IBD), the invasive, costly, and time-consuming procedure limits its routine applications. We...
8.
Zhang L, Li Y, Dai Y, Wang D, Wang X, Cao Y, et al.
Sci Rep
. 2021 Sep;
11(1):18875.
PMID: 34556750
Metabolic pattern reconstruction is an important factor in tumor progression. Metabolism of tumor cells is characterized by abnormal increase in anaerobic glycolysis, regardless of high oxygen concentration, resulting in a...
9.
Zhang L, Li Y, Wang X, Ping Y, Wang D, Cao Y, et al.
J Cancer
. 2021 May;
12(12):3626-3647.
PMID: 33995639
Compared to non-recurrent type, recurrent prostate adenocarcinoma (PCa) is highly fatal, and significantly shortens the survival time of affected patients. Early and accurate laboratory diagnosis is particularly important in identifying...
10.
Wang D, Sang Y, Sun T, Kong P, Zhang L, Dai Y, et al.
Int J Oncol
. 2021 Mar;
58(5).
PMID: 33760107
MicroRNAs (miRNAs/miRs) are a class of small non‑coding RNAs that maintain the precise balance of various physiological processes through regulating the function of target mRNAs. Dysregulation of miRNAs is closely...